膝下动脉病变血管内治疗模式的系统评价与网状Meta分析
该网状Meta分析纳入23项随机对照试验共3091例慢性肢体威胁性缺血患者,比较PTA、DCB、DES、BMS、BVS及斑块旋切等7种血管内治疗模式的疗效与安全性。结果显示各模式30天主要安全终点无显著差异;6个月时DCB、斑块旋切联合DCB及DES在原发疗效终点上获益最大。
要点
- 膝下病变各血管内治疗模式30天主要安全终点无显著差异。
- 6个月时DCB、斑块旋切联合DCB及DES较PTA显著改善疗效终点。
- BMS在任何时间点均未显示优于PTA的获益。
核心结论
- 对于CLTI患者的膝下病变,DCB、斑块旋切联合DCB、DES及BVS较PTA显示出更优的疗效结局。
- 局部抗增殖药物递送(无论DES、DCB或BVS)对于改善膝下动脉病变的通畅性和疗效是必要的。
- 斑块旋切联合药物递送显示出有前景的潜力。
研究设计与样本
- 系统检索MEDLINE、EMBASE和Cochrane数据库2005年1月1日至2025年1月12日发表的随机对照试验。
- 遵循PRISMA指南,前瞻性注册于PROSPERO(CRD42022323480)。
- 共纳入23项研究、3091例接受PTA、DCB、DES、BMS、BVS或斑块旋切治疗的患者。
- 采用频率学派框架、随机效应模型进行网状Meta分析,以常规PTA为参照干预。
主要发现
- 主要安全终点(30天全因死亡、大截肢和靶肢体任何再干预的复合终点)在各治疗模式间无显著差异。
- 6个月时,DCB较PTA显著提高主要复合终点无事件率(OR 3.68;95%CI 1.37-9.92)。
- 6个月时,斑块旋切联合DCB(OR 7.65;95%CI 1.03-56.98)和DES(OR 5.48;95%CI 1.54-19.49)较PTA显著提高原发通畅率。
- 12个月时,斑块旋切联合DCB的原发通畅获益持续存在,BVS在主要复合终点无事件率上排名第一。
- BMS在任何时间点均未显示优于PTA的获益。
关键数值与推荐
- 主要安全终点为30天全因死亡、大截肢和靶肢体任何再干预的复合终点。
- 主要疗效终点包括6个月主要复合终点(大截肢、靶病变闭塞和临床驱动的靶病变血运重建)无事件率及原发通畅率(免于二值再狭窄和CD-TLR)。
临床怎么用
- 对于CLTI患者的膝下动脉病变,可优先考虑DCB、DES或斑块旋切联合DCB等局部药物递送策略以改善通畅性。
- BMS在膝下病变中未显示优于PTA,选择时需权衡。
- 斑块旋切联合药物递送在12个月时仍显示原发通畅获益,可作为有前景的治疗选择。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular revascularization of below-the-knee lesions is a crucial treatment for patients with chronic limb-threatening ischemia (CLTI). However, the optimal approach to revascularizing infrapopliteal arteries remains uncertain. This study aims to compare the safety and efficacy outcomes of various endovascular treatment modalities for infrapopliteal artery disease and provide an evidence-based update through a network meta-analysis. METHODS: We performed a systematic literature search in MEDLINE, EMBASE, and the Cochrane Database for randomized controlled trials published between January 01, 2005, and January 12, 2025. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was prospectively registered in PROSPERO database (CRD42022323480). The primary safety outcome was major adverse events defined as a composite of all-cause death, major amputation, and any re-intervention of the target limb at 30 days. The primary efficacy outcomes included freedom from composite of major amputation, target lesion occlusion, and clinically driven target lesion revascularization (CD-TLR) and primary patency defined as freedom from binary restenosis and CD-TLR at 6 months. The network meta-analysis was conducted in the frequentist framework using random effects model and conventional percutaneous transluminal angioplasty (PTA) as the reference intervention. Treatment effects were reported as odds ratio (OR) with 95% confidence interval (CI) compared with conventional PTA and interventions were ranked using P-scores. RESULTS: Twenty-three studies including 3091 patients treated with PTA, paclitaxel drug-coated balloons (DCB), drug-eluting stents (DES), bare metal stents (BMS), bioresorbable vascular scaffold (BVS), and atherectomy were included. There were no significant differences in the primary safety outcome between different treatment modalities. At 6 months, DCB, atherectomy with DCB, and DES produced the largest benefit for primary efficacy outcomes. DCB (OR, 3.68; 95% CI, 1.37-9.92) had a higher freedom from the primary composite, and atherectomy with DCB (OR, 7.65; 95% CI, 1.03-56.98) and DES (OR, 5.48; 95% CI, 1.54-19.49) had higher primary patency compared with PTA. At 12 months, the benefit of atherectomy with DCB was sustained for primary patency, and BVS was ranked first for freedom from the primary composite. There was no benefit of BMS compared with PTA at any timepoint. CONCLUSIONS: This network meta-analysis evaluating 7 endovascular treatment modalities provides evidence of improved efficacy outcomes with DCB, atherectomy with DCB, DES, and BVS compared with PTA for treating infrapopliteal lesions in patients with CLTI.Clinical ImpactLocal antiproliferative drug delivery, whether by balloon-expandable sirolimus/everolimus DES or paclitaxel DCB or everolimus BVS, is necessary to improve patency and efficacy outcomes for the treatment of infrapopliteal artery disease. Furthermore, combining atherectomy with drug delivery shows promising potential. Emerging endovascular targeted drug delivery therapies with limus-based DCB or scaffolds promise to provide greater drug transfer efficiency and a more effective therapeutic alternative that overcomes the limitations of metallic stents in one of the most challenging vascular beds.
引用
- Tirziu D, Saleh A, Huang H, et al. Safety and Efficacy of Endovascular Treatment Modalities for Below-the-Knee Arterial Disease: A Systematic Review and Network Meta-analysis. J Endovasc Ther. 2025. PMID: 40586349. doi:10.1177/15266028251344809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。